UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Pharmacological rationale for tapentadol therapy: a review of new evidence

Romualdi, P; Grilli, M; Canonico, PL; Collino, M; Dickenson, AH; (2019) Pharmacological rationale for tapentadol therapy: a review of new evidence. Journal of Pain Research , 12 pp. 1513-1520. 10.2147/JPR.S190160. Green open access

[thumbnail of jpr-190160-pharmacological-rationale-for-tapentadol-therapy-a-review-o-051519.pdf]
Preview
Text
jpr-190160-pharmacological-rationale-for-tapentadol-therapy-a-review-o-051519.pdf - Published Version

Download (1MB) | Preview

Abstract

Chronic pain could be considered as a neurological disorder. Therefore, appropriate selection of the therapy, which should consider the pathophysiological mechanisms of pain, can result in a successful analgesic outcome. Tapentadol is an analgesic drug which acts both as a μ-opioid receptor (MOR) agonist and as a noradrenaline reuptake inhibitor (NRI), thereby generating a synergistic action in terms of analgesic efficacy, but not for the burden of adverse effects. Therefore, tapentadol can be defined as the first “MOR-NRI” drug. This molecule holds the potential to address at least some of the current limitations of analgesic therapy due to its unique mechanism of action and has shown to be safe and effective in the treatment of chronic pain of cancer and noncancer etiologies including nociceptive, neuropathic and mixed pain. In particular, the MOR component of tapentadol activity predominantly allows for analgesia in nociceptive pain; on the other hand, the NRI component contributes, now in a predominant manner, for analgesic efficacy in cases of neuropathic pain states. This paper will discuss recent pieces of evidence on the pathophysiology of pain, the background on tapentadol and then present some new studies on how the unique mechanism of action of tapentadol provides a key role in its analgesic efficacy in a number of pain states and with a favorable safety profile.

Type: Article
Title: Pharmacological rationale for tapentadol therapy: a review of new evidence
Open access status: An open access version is available from UCL Discovery
DOI: 10.2147/JPR.S190160
Publisher version: https://doi.org/10.2147/JPR.S190160
Language: English
Additional information: © 2019 Romualdi et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Ltd, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Keywords: tapentadol, neuropathic pain, pain chronicization
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > Div of Biosciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > Div of Biosciences > Neuro, Physiology and Pharmacology
URI: https://discovery.ucl.ac.uk/id/eprint/10077398
Downloads since deposit
70Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item